The present study was conducted to determine whether Valyl-Tyrosine (VY) has an antihypertensive effect on high-normal blood pressure and mild essential hypertension, as well as spontaneous hypertensive rats (SHR). A randomised double-blind placebo-controlled study was carried out on 29 volunteers. A 100-ml drink containing 3 mg of VY and a 100-ml placebo drink were prepared. The subjects were grouped as VY(16M/1F, 45.5 ؎ 3.2 years, 146.4 ؎ 2.3/90.5 ؎ 1.8 mm Hg) and the placebo (P) (11 M/1F, 48.8 ؎ 3.0 years, 145.5 ؎ 2.4/92.3 ؎ 1.8 mm Hg). At 3 weeks of the control (C) period, a VY-or P-drink was administered twice a day for 4 weeks in the experimental (E) period and during the 4-week recovery period, neither drink was given to either group. Blood pressure (BP) was measured every week in the morning in the sitting position. Blood specimens were
Introduction
The angiotensin I-converting enzyme (ACE) has a significant role in increasing blood pressure (BP) and maintaining hypertension. In the reninangiotensin system, ACE acts on angiotensin (Ang) I to hydrolyze His-Leu from its C-terminal to produce Ang II, ACE activates bradykinin in the kininkallikrein system. Various ACE inhibitors, such as captopril, enalapril and so on, have been synthesized and presently are widely used as effective antihypertensive drugs. 1 But these ACE inhibitors have been found to lead to a high number of incidences of dry coughing as one adverse effect due to the activation of bradykinin. 2 Several ACE inhibitory peptides have been isolated and identified from food materials. [3] [4] [5] The anti- hypertensive effect of food materials on humans via ACE inhibition appears in a few papers. [6] [7] [8] ValylTyrosine (VY) derived from sardine muscle hydrolyzate by Bacillus licheniformis alkaline protease, was confirmed in our previous study to have a remarkable antihypertensive effect in SHR via ACE inhibition. 9 This study was conducted to determine whether VY has an antihypertensive effect on human subjects with high-normal BP and mild hypertension, as does SHR.
Subjects and methods

Subjects
Thirty-four clinically healthy and active volunteers participated in this study. They initially underwent a medical examination, the results of which indicated no significant disorders such as cerebrocardiovascular, renal, endocrine, or metabolic disease, though mild hypertension, hyperlipidaemia, hyperuricaemia or mild glucose intolerance were noted. Casual BP showed high-normal blood pressure 10 or stage I or II hypertension during the control
Journal of Human Hypertension (C)-period. Two subjects had taken ␤-blocker or Ca antagonist at the start of the study and were asked to continue the same doses throughout the study period. The subjects were allocated as VY or placebo (P). All were fully informed of the purpose, procedures and possible hazards and written informed consent was given by the participants. The study was approved by the Human Investigation Review Committee of the Institute of Health Science, Kyushu University.
Drinks
Short chain peptide was prepared as described in a previous paper. 11 Sardine muscle was dissolved in distilled water, and adjusted to pH 9.0 by 20% NaOH. With Bacillus licheniformis alkaline protease (Novo Co., 2.4L, type FG) 0.3% addition, incubated at 50°C for 17 h. After proteolysis, the solution was adjusted to pH 6.0 by 20% HCl and then heated at 98°C for 15 min. The supernatant obtained after centrifugation was filtered through celite cake. The hydrolyzate by alkaline protease was put into a YMC ODS-AQ 120-S50 column and successively eluted with 0%, 10%, 25%, 50% and 99.5% ethanol. The short chain peptide eluted with 10% ethanol had the most potent ACE inhibitory activity. For the final drink, high fractose corn sweetner, honey, stevia extract, flavouring, citric acid and malic acid were added to short chain peptide solution, dispensed in 100 ml glass bottles, pasteurized at 128°C for 10 sec. A placebo-drink was prepared in the same way as was the VY-drink except for the addition of water instead of short chain peptide solution. Table 1 summarises the nutritional compositions and VY concentration in the VY-and placebo (P)-drinks. The contents of composition in both drinks were analysed in the usual way, that of the ACE inhibitory peptides VY were determined by the method of Seki et al.
12
Protocol
Protocol of a randomised double-blind placebocontrolled study was carried out on 29 subjects with high-normal BP and mild hypertension as shown in Figure 1 . The subjects were instructed to avoid changing their ordinary house diet and also not to alter their lifestyles as much as possible during the 11-week study period. A 100 ml drink containing 3 mg VY 12 and 100 ml placebo (P) were prepared. The subjects were administered one of those two drinks. At the start of the experimental (E)-period, five subjects in the P-group withdrew from the study because of problems in making regular BP measurements every week. Thus, 17 and 12 subjects received either VYor P-drink, respectively.
During the 3 weeks of the C-period, all subjects were given the P-drink in the last week. Thereafter, either the VY-or P-drink was taken twice daily for 4 weeks in the E-period. During the 4-week recovery (R) period, neither drink was given.
BP and heart rates (HR) were measured every week three times consecutively, after the subjects had sat quietly for at least 5 min, in the morning at 09.00, using automated BP device (BP-203N, Nippon Colin Co. Ltd, Komaki, Japan). The average of the three consecutive measurements served to indicate individual BP and HR.
Blood specimens were taken in the morning after 12 h fasting on the last day of the C-and E-periods for measurement of blood chemistry, Ang I, II, VY and aldosterone. The 24-h urine was collected on the last day of each period and 24-h urinary sodium (Na), potassium (K) and creatinine excretions were measured. Ang I, II and VY in human plasma was determined by the fluorometric HPLC method with naphthalene-2,3-dialdehyde, 13 and plasma aldosterone (PAC) was determined by a radioimmunoassay method.
Statistical methods
Differences between weekly values were evaluated by the Student's paired t-test and those between the two group were, by the Student's t-test, Wilcoxons' rank-sum test and ANOVA. All data were expressed as means Ϯ s.e.m. A value of P Ͻ 0.05 was considered statistically significant.
Results
Subject features for both groups are listed in Table  2 . The VY-and P-group were essentially the same in age, body composition, percentage of alcohol consumption, smoking, and positive family history of hypertension and BP during the C-period. The 24-h urinary Na, K and creatinine excretions and urinary Na/K ratio were not significantly different between the two groups as shown in Table 2 .
Changes in systolic (S) and diastolic (D) BP in the two groups are shown in Figure 2 . Reduction in SBP and DBP was 9.7 and 5.3 mm Hg (both, P Ͻ 0.001) at 1 week, and 9.3 and 5.2 mm Hg (both, P Ͻ 0.001) at 4 weeks following the start of VY-drink administration, respectively, compared to the average values of the C-period (146.4 Ϯ 2.3 mm Hg in SBP and 90.5 Ϯ 1.8 mm Hg in DBP). Neither SBP nor DBP significantly changed in the P-group while BP in the VYgroup increased gradually by the end of the R-period as shown in Figure 2 . HR did not change throughout the study and was basically the same for the two groups although the data were not shown. No adverse effect such as dry coughing or allergic Figure 1 Protocol of a randomised double-blind placebo-controlled study of high-normal blood pressure and mild hypertensive subjects. Ruled box, VY-drink: Valyl-Tyrosine 3 mg twice a day; tinted boxes, P-drink: Placebo drink twice a day. phenomena were observed in the VY-group during the E-and R-periods.
The subjects (n = 17) consisted of two groups; high normal BP group (HNBP, n = 4) and mild hyperten- The antihypertensive effects of the VY drink were found to be significant in both the HNBP group and the HT group. A significance test was performed for the subjects, excluding two female subjects, but the results of the test were not affected by joining the two. Figure 3 shows plasma Ang I, II, VY and aldosterone concentrations in the C-and E-period in both groups. No significant differences were found during the C-period between the VY group and the placebo group as seen in Figure 3 . For the VY group, plasma Ang I and VY significantly increased while plasma Ang II and aldosterone significantly decreased in the E-period, compared to the C-period. For the placebo group, there were no significant changes in plasma Ang I, II, VY and aldosterone concentrations during
Journal of Human Hypertension Figure 3 Plasma angiotensin I, II, VY and aldosterone concentrations before and after experimental period in VY and Placebo groups. *P Ͻ 0.05, **P Ͻ 0.01 (vs control period). Black bar = control period, ruled bar = experimental period (4 weeks after VY intake).
the E-period. No significant differences were detected between the C-and E-period in any parameters, except for serum chloride concentration in the VY group. There were also no significant differences in the urinary Na, K and creatinine excretions and the urinary Na/K ratio of the two groups.
Discussion
VY, Ang (3-4), has been thought to be the final product of decapeptides and rarely considered to have any biological activities up to the time of our first report on spontaneous hypertensive rats (SHR), 9 in which VY was shown to have a long-acting depressor effect without harmful influence on SHR. VY-drink was thus examined here for possible beneficial effects on human mild hypertensive and high-normal BP subjects. Dosage was based on rat experimental data. SBP and DBP were noted to significantly decrease with this dosage during the Eperiod and increase again until the level of the Cperiod by the end of R-period. BP never changed in the P-group throughout the study. VY would thus appear probably to have remarkable antihypertensive effects not only on human mild hypertensive but high-normal BP subjects as well, to the same extent as SHR. As the next step, the minimal effective VY dose for lowering BP should thus be determined.
The peptides with an average molecular weight of 315 and an average chain length of 2.67 prepared from sardine proteins by alkaline proteases had no bitter taste and little fish flavour; there was a high resistance to hydrolysis by pig intestinal fluid after pepsin digestion, which showed the potent ACE inhibitory activity and the capacity to reduce blood pressure in SHR. 9 The acute toxicity of the short chain peptides, its LD 50 value (mg/kg) was 3000 or above, had no antigenicity by oral administration. 14 The content of Val-Tyr was 3 mg per 2 g of the short chain peptides, representing 1.3% of the total ACE inhibitory activity of the short chain peptides. 12 Although the antihypertensive mechanism of VY is not clear, Ang I significantly increased and Ang II and aldosterone significantly decreased at 4 weeks after the start of VY administration, with a significant reduction in both SBP and DBP, suggesting that VY may inhibit the conversion from Ang I to Ang II, but not Ang II receptor antagonist. To explain the absence of adverse effects, antihypertensive mechanisms other than the accumulation of bradykinin by kininase II should be considered. Captopril inhibited degradation of bradykinin by dipeptidyl peptidase activity of ACE, but Val-Tyr did not inhibit. 15 We tried to illustrate our hypothesis in Figure 4 . Endogenous plasma VY concentration was higher in normotensives 16, 17, 19 and plasma VY increased following exogenous VY administration, together with a significant decrease in BP. 17 VY would thus appear to be a predominant metabolite from Ang I and may possibly regulate the BP via ACE. 18, 19 The production of VY may have a close association with the renin-angiotensin system since plasma VY significantly increased with plasma renin activity in normotensive subjects of our previous study. 18, 19 VY was previously shown to be a direct and predominant metabolite from Ang I and plasma VY to be significantly lower in hypertensive than in normotensive subjects. 17, 19 No significant differences were found during the C-period between the VY-group and the P-group as seen in Figure 3 . When the renin-angiotensin system is activated, further antihypertensive effects of VY might occur, but such effects were not observed in the present subjects whose plasma levels of angiotensin II and aldosterone were high. This depressor effect could thus be due to a feedback mechanism of VY in the conversion from Ang I to Ang II. Since antihypertensive effects appear from 2 h after VY intake, BP is thought to have recovered 24 h after the intake. In the present study, the hypotensive effects might have markedly appeared since the BP was measured in the morning, 2 to 3 h after VY intake. Even after the discontinuation of the intake, mild recovery was noted without any rebound effects on BP. If time course changes of blood level are monitored in the healthy subjects administered with the VY drink, this would be clarified. The antihypertensive effect of dipeptide, VY, on hypertensive subjects is presented here for the first time, but the mechanism still remains to be fully determined.
